Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients

Withdrawn University of Minnesota

RandomizedCrossoverQuadruple-blindOther

Summary

Hypothesis 1: Treatment of heart transplant recipients with sildenafil, a PDE-5 inhibitor, will improve small artery elasticity (SAE) when compared to placebo. Hypothesis 2: PDE-5 inhibition will improve endothelial function, resulting in increased production of nitric oxide, reduced activation of circulating endothelial cells, and increased endothelial progenitor cells.

Timeline

Start: 2010-10
Primary completion: 2015-03
Completion: 2015-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sildenafil	Unknown	20 mg	Oral

Indications

No indication recorded.